NASDAQ: MLYS
Mineralys Therapeutics Inc Stock Ownership - Who owns Mineralys Therapeutics?

Insider buying vs selling

Have Mineralys Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Daphne KarydasDirector2026-06-173,000$12.02
$36.06kBuy
Daphne KarydasDirector2026-06-173,000$25.00
$75.00kSell
David Malcom RodmanChief Medical Officer2026-06-174,167$14.25
$59.38kBuy
David Malcom RodmanChief Medical Officer2026-06-17417$15.44
$6.44kBuy
David Malcom RodmanChief Medical Officer2026-06-174,584$25.00
$114.60kSell
David Malcom RodmanChief Medical Officer2026-06-153,542$10.20
$36.13kBuy
David Malcom RodmanChief Medical Officer2026-06-159,890$23.81
$235.49kSell
David Malcom RodmanChief Medical Officer2026-06-126,349$23.93
$151.90kSell
David Malcom RodmanChief Medical Officer2026-06-126,349$1.08
$6.86kBuy
David Malcom RodmanChief Medical Officer2026-06-102,170$25.00
$54.25kSell

1 of 14

MLYS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MLYS insiders and whales buy or sell their stock.

MLYS Shareholders

What type of owners hold Mineralys Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Srinivas Akkaraju14.72%12,140,369$323.91MInsider
Samsara Biocapital GP LLC13.03%10,749,832$286.81MInsider
Brian Taylor Slingsby9.59%7,910,038$211.04MInsider
Catalys Pacific LLC9.58%7,903,838$210.87MInstitution
Ra Capital Management LP9.32%7,692,750$205.24MInstitution
Samsara Biocapital LLC7.12%5,871,018$156.64MInstitution
Fmr LLC5.89%4,861,104$129.69MInstitution
Blackrock Inc5.43%4,481,582$119.57MInstitution
Ra Capital Management LP4.53%3,734,458$99.64MInsider
Wellington Management Group LLP4.07%3,359,068$89.62MInstitution

1 of 3

MLYS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MLYS70.05%29.95%Net BuyingNet Selling
AUPH57.47%14.58%Net BuyingNet Buying
PHVS90.09%5.20%Net SellingNet Selling
OCUL84.70%15.30%Net SellingNet Selling
KOD73.18%26.82%Net BuyingNet Buying

Mineralys Therapeutics Stock Ownership FAQ

Who owns Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ: MLYS) is owned by 109.49% institutional shareholders, 46.80% Mineralys Therapeutics insiders, and 0.00% retail investors. Srinivas Akkaraju is the largest individual Mineralys Therapeutics shareholder, owning 12.14M shares representing 14.72% of the company. Srinivas Akkaraju's Mineralys Therapeutics shares are currently valued at $323.91M.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.